B O O K - American College of Rheumatology
B O O K - American College of Rheumatology
B O O K - American College of Rheumatology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
INVITED SPEAKER /MODERATOR INDEX<br />
308<br />
Louie, Grant H, MD, MHS<br />
Finding and Using Secondary Data Resources<br />
for Research: Beyond the National Health and<br />
Nutrition Examination Survey and the Usual<br />
Suspects . . . . . . . . . . . . . . . . . . . 103<br />
Disclosure: Nothing to Disclose<br />
Lovell, Daniel J, MD, MPH<br />
2010 ACR Recommendations for the Treatment<br />
<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />
Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />
& Rheumatism & Arthritis and Rheumatism, 9;<br />
Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />
Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />
Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />
Wyeth Pharm., 9; Xoma, Inc., 5<br />
Update on Safety Issues in the Treatment <strong>of</strong><br />
Rheumatic Diseases – From the Food and Drug<br />
Administration and Beyond . . . . . . . . . 77<br />
Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />
& Rheumatism & Arthritis and Rheumatism, 9;<br />
Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />
Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />
Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />
Wyeth Pharm., 9; Xoma, Inc., 5<br />
Lundberg, Ingrid E, MD, PhD<br />
Inflammatory Myopathy Update. . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
M<br />
MacDonald, Patricia A, BSN, NP<br />
Adaptations and Solutions to Help People with<br />
Scleroderma Continue to Work . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
MacLean, Catherine H, MD, PhD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: WellPoint, 3<br />
Maksymowych, Walter P, MD<br />
Ankylosing Spondylitis: Disease Modification. .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
Disclosure: Abbott, 2, 5; Merck, 2, 5; Pfizer, 2, 5<br />
Mandelin, Arthur M, MD, PhD<br />
Adult Musculoskeletal Upper/Lower<br />
Examinations . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Abbott, 8; UCB, 8<br />
Mandell, Brian F, MD, PhD<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />
Disclosure: merck, 9; takeda, 5; url, 5<br />
Perioperative Management <strong>of</strong> Selected<br />
Problems in Patients with Rheumatic Disease<br />
. . . . . . . . . . . . . . . . . . . . . . . . .122<br />
Disclosure: merck, 9; takeda, 5; url, 5<br />
Synovial Fluid Analysis and Crystal<br />
Identification. . . . . . . . . . . . . . 30, 68, 76<br />
Disclosure: merck, 9; takeda, 5; url, 5<br />
Mandl, Thomas, MD, PhD<br />
Sjögren’s Syndrome . . . . . . . . . . . . . . 92<br />
Marcus, Donald M, MD<br />
CAM is a SCAM! Complementary and<br />
Alternative “Medicince” Has No Place in<br />
<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />
Disclosure: Nothing to Disclose<br />
Marder, Wendy, MD<br />
Reproductive and Sexual Health Issues for<br />
Women with Rheumatic Disease. . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
Maricic, Michael J, MD<br />
Osteoporosis: Novel Treatments . . . . . . . 36<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
<strong>Rheumatology</strong> Practice 101: Starting Out in<br />
Practice for The Graduating Fellow . . . . .130<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
REF Oscar S. Gluck, MD, Memorial Lectureship<br />
- Osteoimmunology: Crosstalk Between the<br />
Immune and Bone Systems: Biologic and Clinical<br />
Implications . . . . . . . . . . . . . . . . . . 28<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
Marshak-Rothstein, Ann, PhD<br />
The Immunology <strong>of</strong> B Cells: From Antibodies to<br />
Immunoregulation . . . . . . . . . . . . . . 20<br />
Disclosure: Idera Pharmaceuticals, 5<br />
Session III: Factors Promoting B Cell<br />
Autoreactivity and Protective Immunity. . . 23<br />
Disclosure: Idera Pharmceuticals, 5<br />
Toll-like Receptors Activation <strong>of</strong> B cells in<br />
Autoimmune Disease . . . . . . . . . . . . . 28<br />
Disclosure: Idera Pharmceuticals, 5<br />
Toll-Like Receptor Signaling in B Cells and<br />
Atoimmune Disease. . . . . . . . . . . . . . 23<br />
Disclosure: Idera Pharmceuticals, 5<br />
Martinez-Lavin, Manuel, MD<br />
Fibromyalgia . . . . . . . . . . . . . . . . . . 57<br />
Disclosure: Nothing to Disclose<br />
Massarotti, Elena M, MD<br />
Systemic Lupus Erythematosus: Difficult to Treat<br />
Systemic Lupus Erythematosus . . . . . . . 97<br />
Disclosure: Cypress Bioscience, 9; EMD Serono,<br />
9; Human Genome Sciences, 5; NIH Ace Grant--<br />
Subcontract, 9; Up to Date, 9<br />
Matteson, Eric L, MD<br />
Infections in Patients on Tumor Necrosis Factor<br />
Therapy . . . . . . . . . . . . . . . . . 56, 130<br />
Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />
centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />
2; human genome sciences, 2; mayo<br />
foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB, 2<br />
Interstitial Lung Diseases in the Rheumatic<br />
Diseases . . . . . . . . . . . . . . . . . . . .109<br />
Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />
centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />
2; human genome sciences, 2; mayo<br />
foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB, 2<br />
Polymyalgia Rheumatica . . . . . . . . . . . 91<br />
Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />
centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />
2; human genome sciences, 2; mayo<br />
foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB,<br />
2; Mauri, Claudia, PhD<br />
B cell Effectors and Regulators . . . . . . . 113<br />
Disclosure: Nothing to Disclose<br />
Mayes, Maureen D, MD, MPH<br />
Systemic Sclerosis: How to Perform Skin<br />
Scores . . . . . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
McCarthy, Geraldine M, MD<br />
Crystal: Pseudogout . . . . . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
McInnes, Iain B, PhD<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />
Disclosure: BMS, 2, 5; Pfizer, 2; Roche, 2;<br />
Schering Plough, 2, 8<br />
McLean, Robert R, DSc, MPH<br />
Finding and Using Secondary Data Resources<br />
for Research: Beyond the National Health and<br />
Nutrition Examination Survey and the Usual<br />
Suspects . . . . . . . . . . . . . . . . . . . 103<br />
Disclosure: Nothing to Disclose<br />
How to Understand and Apply the Results <strong>of</strong> a<br />
Journal Article: What You Really Need to Know<br />
About Statistics . . . . . . . . . . . . . . . .134<br />
Disclosure: Nothing to Disclose<br />
You’ve Got the Power: How to Use and Teach<br />
Statistical Power for Studies and Grants. . . 47<br />
Disclosure: Nothing to Disclose<br />
McLellan, Alastair R, MD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
McMahan, Zsuzsanna H, MD<br />
Immunizations and Rheumatic Diseases - An<br />
Update . . . . . . . . . . . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
Thieves’ Market: Show Me Your Best<br />
Cases . . . . . . . . . . . . . . . . . . . . . . 69<br />
Disclosure: Nothing to Disclose<br />
McNally, Bernadette, MS, PAC<br />
The Multidisciplinary Approach to Hereditary<br />
Periodic Fever Syndromes . . . . . . . . . . 58<br />
Disclosure: Nothing to Disclose<br />
Using Pharmacogenomics to Improve Therapy<br />
for Pediatric Patients . . . . . . . . . . . . . 96<br />
Disclosure: Nothing to Disclose<br />
Mease, Philip J, MD<br />
Psoriatic Disease: Clinical Spectrum and<br />
Comprehensive Treatment Strategies . . . . 69<br />
Disclosure: Abbott, Amgen, BiogenIDEC, BMS,<br />
Centocor, Genentech, Roche, Wyeth and Pfizer,<br />
2; Abbott, Amgen, BiogenIDEC, BMS, Centocor,<br />
Genentech, Roche, Wyeth, Pfizer, UCB, 5<br />
Disclosure: Abbott, Amgen, BiogenIDEC, BMS,<br />
Centocor, Genentech, Roche, Wyeth, Pfizer,<br />
UCB, 8<br />
Meffre, Eric, PhD<br />
Session IV: B Cell Regulation and B Cell<br />
Regulators . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
B cell Effectors and Regulators . . . . . . . 113<br />
Disclosure: Nothing to Disclose<br />
Melton, Alton, MD<br />
Immunodeficiency Syndromes . . . . . . . . 52<br />
Disclosure: Nothing to Disclose<br />
Merkel, Peter A, MD, MPH<br />
Vasculitis: Update . . . . . . . . . . . . . 65, 97<br />
Disclosure: Biovitrum, 5; Bristol Myers Squibb,<br />
2; Celgene, 2; EMD Serono, 5; Genentech, 2;<br />
Genzyme, 5; Nordic Group, 5; Novartis, 5; Smith<br />
Kline Beecham, 5<br />
Takayasu’s Arteritis . . . . . . . . . . . . . .112<br />
Disclosure: Biovitrum, 5; Bristol Myers Squibb,<br />
2; Celgene, 2; EMD Serono, 5; Genentech, 2;<br />
Genzyme, 5; Nordic Group, 5; Novartis, 5; Smith<br />
Kline Beecham, 5